SCHEMBL3661357

SCHEMBL3661357

CCC(C)NC(NC(C)CC)(c1ccccc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.40
ALDH1A1 P00352 2/20 0.40
TP53 P04637 1/20 0.40
HSP90AA1 P07900 1/20 0.40
CYP3A4 P08684 1/20 0.40
THRB P10828 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
CASP1 P29466 1/20 0.40
HIF1A Q16665 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CACNA1F O60840 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
ADRA2B P18089 1/20 0.40
CHRM3 P20309 1/20 0.40
ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11128720 0.84 SMN1; SMN2 (0.46) KCNN4SMN1; SMN2ALDH1A1L3MBTL1CACNA1F
SCHEMBL6566499 0.83 KCNN4 (0.52) KCNN4SMN1; SMN2ALDH1A1TP53HSP90AA1
SCHEMBL16609226 0.83 KCNN4 (0.52) KCNN4SMN1; SMN2ALDH1A1TP53HSP90AA1
SCHEMBL24453542 0.82 CACNA1F (0.43) KCNN4SMN1; SMN2ALDH1A1TP53HSP90AA1
SCHEMBL11131986 0.81 POLB (0.40) KCNN4SMN1; SMN2ALDH1A1CACNA1FCHRM2
SCHEMBL11128026 0.80 CNR2 (0.39) KCNN4SMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL18799433 0.79 CACNA1F (0.44) KCNN4SMN1; SMN2ALDH1A1TP53HSP90AA1
SCHEMBL11129972 0.78 ADH1B (0.40) ALDH1A1MEN1KMT2ASIGMAR1
SCHEMBL11129962 0.78 ADH1B (0.40) ALDH1A1MEN1KMT2ASIGMAR1
SCHEMBL11128915 0.78 ADH1B (0.40) ALDH1A1MEN1KMT2ASIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122011330-A Micro-crosslinking polyurea polyurethane, application method and product thereof 李宁体育科技(北京)有限公司 2026-05-12 CN claimed
CN-120059112-A Prefabricated polyurethane runway coiled material and preparation method thereof 万华化学(北京)有限公司 2025-05-30 CN claimed
WO-2025097688-A1 ADHESIVE COMPOSITION AND PREPARATION METHOD THEREFOR, BATTERY PACK, AND ELECTRIC DEVICE 宁德时代新能源科技股份有限公司 2025-05-15 WO claimed
CN-119955462-A Adhesive composition, preparation method thereof, battery pack and electric device 宁德时代新能源科技股份有限公司 2025-05-09 CN claimed
CN-119371626-A Double-component solvent-free hand brush polyurea material and preparation method and application thereof 万华化学(北京)有限公司 2025-01-28 CN claimed
CN-118772757-A Primer-free intrinsic flame-retardant anti-explosion polyurea coating and preparation method thereof 青岛爱尔家佳新材料股份有限公司 2024-10-15 CN claimed
CN-118685147-A Low-hardness fast-curing two-component polyurethane structural adhesive 铠博新材料(天津)有限公司 2024-09-24 CN claimed
CN-118530428-A Synthesis method of fluorocarbon chain grafted graphite reinforced wear-resistant polyurethane 浙江艾领创矿业科技有限公司 2024-08-23 CN claimed
CN-117316494-A High-pass TPU conductive film and preparation method thereof 东莞市雄林新材料科技股份有限公司 2023-12-29 CN claimed
CN-116731496-A Thermoplastic elastomer foaming material for shoes and preparation method thereof 李宁(中国)体育用品有限公司 2023-09-12 CN claimed
US-20160095811-A1 METHODS OF TREATING AND/OR PREVENTING NAIL DISORDERS AND/OR IMPROVING THE APPEARANCE OF A NAIL NAIL GENESIS LLC 2016-04-07 US claimed
EP-2207535-B1 POLY(UREA-URETHANE) COMPOSITIONS USEFUL AS TOPICAL MEDICAMENTS AND METHODS OF USING THE SAME CHESSON LAB ASSOCIATES INC (US) 2014-08-27 EP claimed
US-20140212370-A1 POLY(UREA-URETHANE) COMPOSITIONS USEFUL AS TOPICAL MEDICAMENTS AND METHODS OF USING THE SAME CHESSON LABORATORY ASSOCIATES, INC. (US) 2014-07-31 US claimed
US-8771725-B2 Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same CHESSON LABORATORY ASSOCIATES, INC. (US) 2014-07-08 US claimed
EP-2207535-A2 POLY(UREA-URETHANE) COMPOSITIONS USEFUL AS TOPICAL MEDICAMENTS AND METHODS OF USING THE SAME Chesson Laboratory Associates, Inc. (US) 2010-07-21 EP claimed
WO-2009051648-A2 POLY(UREA-URETHANE) COMPOSITIONS USEFUL AS TOPICAL MEDICAMENTS AND METHODS OF USING THE SAME CHESSON LABORATORY ASSOCIATES, INC. (US) 2009-04-23 WO claimed
US-20090098194-A1 POLY(UREA-URETHANE) COMPOSITIONS USEFUL AS TOPICAL MEDICAMENTS AND METHODS OF USING THE SAME EPI HEALTH, LLC 2009-04-16 US claimed
US-20080253984-A1 METHODS OF INHIBITING THE GROWTH OF ONYCHOMYCOSIS AND URUSHIOL-INDUCED ALLERGIC CONTACT DERMATITIS NAIL GENESIS LLC 2008-10-16 US claimed
US-20040214978-A1 Moisture-curing, hot-melt polyurethane adhesive WORTHEN INDUSTRIES, INC. 2004-10-28 US claimed
EP-1471087-A1 Moisture-curing, hot-melt polyurethane adhesive WORTHEN INDUSTRIES INC. (US) 2004-10-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140212370-A1 POLY(UREA-URETHANE) COMPOSITIONS USEFUL AS TOPICAL MEDICAMENTS AND METHODS OF USING THE SAME PUF60, UROD, UNG KCNN4 4232/4885SMN1; SMN2 3988/4885ALDH1A1 1205/4885
US-20160095811-A1 METHODS OF TREATING AND/OR PREVENTING NAIL DISORDERS AND/OR IMPROVING THE APPEARANCE OF A NAIL POLR1C, NACA, PIK3C3 KCNN4 3071/4885SMN1; SMN2 1529/4885ALDH1A1 1039/4885
US-20090098194-A1 POLY(UREA-URETHANE) COMPOSITIONS USEFUL AS TOPICAL MEDICAMENTS AND METHODS OF USING THE SAME PUF60, UROD, UNG KCNN4 4232/4885SMN1; SMN2 3988/4885ALDH1A1 1205/4885
US-20080253984-A1 METHODS OF INHIBITING THE GROWTH OF ONYCHOMYCOSIS AND URUSHIOL-INDUCED ALLERGIC CONTACT DERMATITIS DPM1, AOC1, POLR1C KCNN4 3102/4885SMN1; SMN2 4758/4885ALDH1A1 815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.